Business Wire

AVANZANITE-BIOSCIENCE

27.8.2024 07:01:26 CEST | Business Wire | Press release

Share
Avanzanite Bioscience Reports European Commission's Authorisation of Orphan Medicinal Product AKANTIOR®

Avanzanite Bioscience B.V., a commercial-stage specialty pharmaceutical company, focused on bringing novel medicines for rare diseases to market, announced today that the European Commission (EC) granted marketing authorisation of AKANTIOR® (polihexanide) for the treatment of acanthamoeba keratitis (AK) in adults and children from 12 years of age. The formal approval by the EC follows previously reported positive opinion of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) as well as subsequent positive recommendation of the EMA Committee for Orphan Medicinal Products (COMP). Following more than 16 years of research & development (R&D), AKANTIOR is the first and only authorised medicinal product for the treatment of AK globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240826744342/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adam Plich, Founder & CEO of Avanzanite Bioscience (Photo: Business Wire)

“Our studies have shown that with AKANTIOR, when used as monotherapy with the treatment delivery protocol established for use in the trial, medical cure rates of over 85% can be achieved. As the first authorised drug, I expect this to become the standard of care for this severe disease,” stated John Dart, Principal Investigator of the pivotal phase III ODAK trial, and Professor at the Moorfields Eye Hospital and the University College London Institute of Ophthalmology. “AKANTIOR can be expected to improve the cure rate without surgery, reducing both the high rates of morbidity – principally anxiety, pain, time off normal activities, time to cure – and blindness rates associated with current unlicensed, often compounded, combination therapies.”

In March 2024, results of the 135-patient, phase III, pivotal Orphan Drug for Acanthamoeba Keratitis (ODAK) trial, were published in Ophthalmology, demonstrating AKANTIOR’s absolute efficacy and safety. The trial showed that 84.8% of patients receiving AKANTIOR were cured. Furthermore, 66.7% of patients treated with AKANTIOR achieved full vision restoration with no patients resorting to optical cornea transplant. Only 7.5% of AKANTIOR-treated patients required a therapeutic cornea transplant.

“As an acanthamoeba keratitis (AK) Warrior, I am optimistic that AKANTIOR will have a significant and positive impact on AK patients,” commented Juliette Vila Sinclair Spence, a rare disease patient advocate and the Chairwoman and Founder of AK Eye Foundation – the first global foundation dedicated exclusively to this condition. “When I was diagnosed with AK, for me, there were no authorised drugs or standardised treatment protocols like AKANTIOR available. I had to rely on various compounded or off-label eye drops without a validated protocol. This approval has reignited my passion and commitment to increasing awareness about this rare eye disease.”

Acanthamoeba keratitis (AK) is a rare, severe, and progressive parasitic corneal infection caused by Acanthamoeba, a free-living amoeba. Urgent medical intervention is necessary as the disease leads to blindness and eye loss. AK often requires single or multiple cornea transplant procedures with comparably low graft survival rates. Patients report unbearable pain and extreme light sensitivity and can rarely work or lead normal lives until symptoms resolve, leaving patients with trauma for life. AK primarily affects contact lens wearers and is responsible for 50% of blindness cases in this demographic. In the absence of anti-amoebal treatment, 80.4% of patients require surgery, such as therapeutic cornea transplant, or eye removal in a historical cohort of 56 patients.

“No one fighting such a devastating rare disease should be left behind. This marketing authorisation is the beginning of a new chapter for the treatment of acanthamoeba keratitis (AK) and a monumental victory for AK patients in Europe,” stated Avanzanite’s Founder & CEO, Adam Plich. “We are grateful to our R&D partners at SIFI, the healthcare professionals, as well as the patients and their families who participated in the trials, for the years of dedication and hard work that made this day possible.”

To date, AKANTIOR has been provided to more than 200 patients across 12 countries through a pre-authorisation distribution program. “At Avanzanite, we are committed to supporting broad access to our innovative therapies and look forward to collaborating with local health authorities in 26 European countries to secure sustainable access agreements so we can save the eyes of as many eligible patients as possible,” Plich concluded.

Avanzanite secured exclusive rights to commercialise AKANTIOR in 26 countries across the European Economic Area and Switzerland through a license and supply agreement with SIFI, a leading international ophthalmic company headquartered in Italy. AKANTIOR is the second rare disease medicine commercialised by Avanzanite, expanding both the company’s portfolio and geographical footprint, in support of the ambition to become a global rare disease company.

ABOUT AKANTIOR®: AKANTIOR (polihexanide) is the first European Commission-approved medicinal product for AK. It is an anti-amoebic polymer granted Orphan Drug Designation (ODD) by the European Medicines Agency ("EMA") and Food and Drug Administration ("FDA"). It acts on both the trophozoites and cysts of the protozoan Acanthamoeba. It is formulated at a unique high 0.8 mg/ml (0.08%) dose strength administered through a validated and standardised, day-only protocol as monotherapy eye drops in single-dose containers. Polihexanide is also being developed for the treatment of fungal keratitis for which it has ODD from both FDA and EMA.

ABOUT AVANZANITE BIOSCIENCE: We believe all patients should benefit from novel orphan or niche medicines regardless of where they live. Our vision is that no one is left behind when facing a debilitating rare disease. We also believe the people who have dedicated their careers to the research & development of novel orphan or niche medicines, deserve to witness how their tremendous efforts impact patients’ lives – the work of these heroes should not lie in vain. We make this happen by acquiring, licensing, or distributing approved or late-stage medicines for rare diseases, unlocking their potential, and commercialising them even where nobody else will. Founded in 2022, Avanzanite is headquartered in Amsterdam, the Netherlands, with commercial infrastructure and technical operations across Europe. Visit www.avanzanite.com for additional information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240826744342/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release

New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud

The Rock-It Company Opens New Regional Office in Nashville16.11.2026 17:00:00 CET | Press release

The expansion demonstrates The Rock-It Company’s dedication to the iconic live music market and opens a new centralized hub that connects live events and luxury goods in a fast-growing region. The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that f

IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 17:00:00 CET | Press release

IQM quantum computers already run at leading supercomputing centers, including Oak Ridge National Laboratory (ORNL), VTT Technical Research Centre of Finland, the Leibniz Supercomputing Centre (LRZ) and CINECA, with users reaching them through Slurm. IQM supports NVIDIA’s investment in making quantum processors a schedulable resource in supercomputing centers by integrating IQM quantum computers with Slurm. IQM’s partner MQSC (Munich Quantum Software Company) has demonstrated the MQSC Orchestrator scheduling IQM systems through the new Slurm capability. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making q

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release

Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye